Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,169 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endocrine Pancreas Disorder Clear all
Recruiting No phase listed Observational

Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts

NCT04473794
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreas Cancer
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 5, 2026, 4:27 AM EDT
Not yet recruiting Not applicable Interventional

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

NCT07787156
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
Interventions
Telephone education session, Online educational materials
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 5, 2026, 4:27 AM EDT
Recruiting No phase listed Observational

ExoLuminate Study for Early Detection of Pancreatic Cancer

NCT05625529
View directory record Official record
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 5, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

NCT00783172
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Opioid Growth Factor (OGF)
Drug · Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Allentown, Pennsylvania • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

NCT02241187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PEGPH20, Cetuximab, DW & DCE-MRI, blood draws
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Not applicable Interventional

MD2Me - Texting to Promote Chronic Disease Management

NCT01253733
View directory record Official record
Conditions
Cystic Fibrosis, Inflammatory Bowel Disease, Type 1 Diabetes, Chronic Disease Management
Interventions
MD2ME
Behavioral
Lead sponsor
Huang, Jeannie, M.D.
Individual
Eligibility
14 Years to 22 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Sep 5, 2026, 4:27 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

NCT05610826
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor, Pancreas Cancer
Interventions
cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT)
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 5, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions
MRTX1133
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 5, 2026, 4:27 AM EDT
Recruiting Phase 2 Interventional

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

NCT05241249
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Bethanechol, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Susan E. Bates
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Preop Chemoradiation Resectable Pancreas

NCT00336648
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Avastin (Bevacizumab), Gemcitabine, Radiation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas Automated Initialization Trial

NCT06017089
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AI-based Advisor system
Device
Lead sponsor
Marc Breton
Other
Eligibility
2 Years to 5 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 4:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

NCT04299880
View directory record Official record
Conditions
Oncology
Interventions
Napabucasin, Nab-paclitaxel, Gemcitabine, Nivolumab, Paclitaxel, Irinotecan, Leucovorin, 5Fluorouracil, Bevacizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Scarborough, Maine • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Not applicable Interventional

Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection

NCT01058746
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
restrictive perioperative fluid management, Liberal perioperative fluid management
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

NCT00005860
View directory record Official record
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 5, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

NCT03118349
View directory record Official record
Conditions
Pancreatic Carcinoma, Tumors That Express CA 19-9
Interventions
MVT-1075, MVT-5873
Drug
Lead sponsor
BioNTech Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 5, 2026, 4:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

NCT06736717
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Onvansertib, NALIRIFOX
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 5, 2026, 4:27 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer

NCT01895790
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancreatic Duct Stent Placement
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 5, 2026, 4:27 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

NCT06447662
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 5, 2026, 4:27 AM EDT
Recruiting Phase 1 Interventional

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT06545942
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Interventions
MOMA-313, Olaparib
Drug
Lead sponsor
MOMA Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Goodyear, Arizona • La Jolla, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer

NCT00003760
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
irofulven
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
3
States / cities
Omaha, Nebraska • Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 5, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Michigan Genetic Hereditary Testing (MiGHT)

NCT05162846
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 5, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ruxolitinib in Pancreatic Cancer Patients

NCT02119663
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Ruxolitinib, Placebo, Capecitabine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
55
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 5, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional Results available

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

NCT03948763
View directory record Official record
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
Interventions
V941, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 5, 2026, 4:27 AM EDT